Confocal Fluorescence Microscopy of the Human Airways in Diagnostics of Lung Transplantation

Sponsor
Boston Children's Hospital (Other)
Overall Status
Withdrawn
CT.gov ID
NCT02395393
Collaborator
(none)
0
1
1
25
0

Study Details

Study Description

Brief Summary

Bronchoscopy-guided tissue sampling is a central technique in many diseases including diagnosing and staging lung cancers, diagnosing interstitial lung diseases, and acute and/or chronic rejections following lung transplantation. Confocal fluorescence microscopy is a novel technique used for real-time microscopic imaging of proximal and distal airways, microvessels, and inflammatory cells. We hypothesize that confocal fluorescence microscopy images of airways and alveolar structures during standard bronchoscopy could help recognize and classify the presence or absence of acute or chronic rejection in lung transplant recipients.

Condition or Disease Intervention/Treatment Phase
  • Device: Alveoflex Confocal MiniprobeTM
N/A

Detailed Description

Bronchoscopy-guided tissue sampling is a central technique in many diseases including diagnosing and staging lung cancers, diagnosing interstitial lung diseases, and acute and/or chronic rejections following lung transplantation. Confocal fluorescence microscopy is a novel technique used for in vivo microscopic imaging of proximal and distal airways including bronchial and alveolar walls, microvessels, and inflammatory cells. We hypothesize that confocal fluorescence microscopy images of bronchiolar and alveolar structures during standard bronchoscopy could help recognize and classify the presence or absence of acute or chronic rejection in lung transplant recipients.

The objectives and outcomes of this study are:
  1. To assess the safety of confocal microscopy imaging in pediatric patients

  2. To create diagnostic criteria for fibered confocal fluorescence microscopy image interpretation of acute and chronic rejections following lung transplantation

  3. To determine the sensitivity and specificity of confocal imaging in these patient groups compared to the transbronchial biopsies

  4. Correlate confocal images to FEV1 results

  5. Correlate with CXRs and/or CT images

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Confocal Fluorescence Microscopy of the Human Airways in Diagnostics of Lung Transplantation
Actual Study Start Date :
Nov 1, 2018
Anticipated Primary Completion Date :
Nov 1, 2020
Anticipated Study Completion Date :
Dec 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Other: Lung transplant recipients

In patients scheduled for bronchoscopy as part of regular clinical care/diagnostic workup, the investigators will offer the patient concurrent confocal microscopy imaging to be performed during the bronchoscopic procedure. A 1.4mm or 1.9mm diameter Alveoflex Confocal MiniprobeTM (MaunaKea Technologies, France) will be deployed down the working channel of the standard bronchoscope and advanced distally into the alveoli.

Device: Alveoflex Confocal MiniprobeTM
-Alveolar imaging

Outcome Measures

Primary Outcome Measures

  1. Sensitivity and specificity of confocal imaging in these patient groups compared to the transbronchial biopsies [One year]

    Correlate confocal images to histolopathologic findings of acute rejection, chronic rejection, and no evidence of rejection

Secondary Outcome Measures

  1. Number of participants with adverse events [One year]

    Monitor for serious adverse events

  2. Correlation of confocal images with FEV1 results [One year]

    Measure the degree of fibrosis/collagen by confocal imaging and compare to FEV1 values

Eligibility Criteria

Criteria

Ages Eligible for Study:
6 Years to 22 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • to be older than six years of age

  • to be undergoing surveillance or clinically indicated bronchoscopies with transbronchial biopsy as part of their routine care

  • to be willing and able to comply with study procedures and provide written informed consent/assent to participate in the study

Exclusion Criteria:
  • to be unwilling to consent

  • to be unable to safely tolerate a bronchoscopic procedure

  • to have any contraindications to short-acting anesthetic agents

  • to have any contraindications to transbronchial biopsies

Contacts and Locations

Locations

Site City State Country Postal Code
1 Boston Children's Hospital Boston Massachusetts United States 02115

Sponsors and Collaborators

  • Boston Children's Hospital

Investigators

  • Study Director: Gary Visner, DO, Boston Children's Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Levent Midyat, MD, Boston Children's Hospital
ClinicalTrials.gov Identifier:
NCT02395393
Other Study ID Numbers:
  • IRB-P00017377
First Posted:
Mar 23, 2015
Last Update Posted:
Sep 10, 2021
Last Verified:
Sep 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Levent Midyat, MD, Boston Children's Hospital

Study Results

No Results Posted as of Sep 10, 2021